Conversely, baseline GPC-3 levels at SVR12 did not predict de novo HCC development in patients without baseline malignancy, thereby limiting its application as a predictive single-time-point biomarker in the surveillance setting. Here, GPC3 is linked to hepatocellular carcinoma.